BACKGROUND: Heart failure is associated with neurological deficits, including cognitive dysfunction. However, the molecular mechanisms underlying reduced cerebral blood flow in the early stages of heart failure, particularly when blood pressure is minimally affected, are not known. METHODS AND RESULTS: Using a myocardial infarction model in mice, we demonstrate a tumor necrosis factor-α (TNFα)-dependent enhancement of posterior cerebral artery tone that reduces cerebral blood flow before any overt changes in brain structure and function. TNFα expression is increased in mouse posterior cerebral artery smooth muscle cells at 6 weeks after myocardial infarction. Coordinately, isolated posterior cerebral arteries display augmented myogenic tone, which can be fully reversed in vitro by the competitive TNFα antagonist etanercept. TNFα mediates its effect via a sphingosine-1-phosphate (S1P)-dependent mechanism, requiring sphingosine kinase 1 and the S1P(2) receptor. In vivo, sphingosine kinase 1 deletion prevents and etanercept (2-week treatment initiated 6 weeks after myocardial infarction) reverses the reduction of cerebral blood flow, without improving cardiac function. CONCLUSIONS: Cerebral artery vasoconstriction and decreased cerebral blood flow occur early in an animal model of heart failure; these perturbations are reversed by interrupting TNFα/S1P signaling. This signaling pathway may represent a potential therapeutic target to improve cognitive function in heart failure.
BACKGROUND:Heart failure is associated with neurological deficits, including cognitive dysfunction. However, the molecular mechanisms underlying reduced cerebral blood flow in the early stages of heart failure, particularly when blood pressure is minimally affected, are not known. METHODS AND RESULTS: Using a myocardial infarction model in mice, we demonstrate a tumor necrosis factor-α (TNFα)-dependent enhancement of posterior cerebral artery tone that reduces cerebral blood flow before any overt changes in brain structure and function. TNFα expression is increased in mouse posterior cerebral artery smooth muscle cells at 6 weeks after myocardial infarction. Coordinately, isolated posterior cerebral arteries display augmented myogenic tone, which can be fully reversed in vitro by the competitive TNFα antagonist etanercept. TNFα mediates its effect via a sphingosine-1-phosphate (S1P)-dependent mechanism, requiring sphingosine kinase 1 and the S1P(2) receptor. In vivo, sphingosine kinase 1 deletion prevents and etanercept (2-week treatment initiated 6 weeks after myocardial infarction) reverses the reduction of cerebral blood flow, without improving cardiac function. CONCLUSIONS: Cerebral artery vasoconstriction and decreased cerebral blood flow occur early in an animal model of heart failure; these perturbations are reversed by interrupting TNFα/S1P signaling. This signaling pathway may represent a potential therapeutic target to improve cognitive function in heart failure.
Authors: T Michael De Silva; Pimonrat Ketsawatsomkron; Christopher Pelham; Curt D Sigmund; Frank M Faraci Journal: Hypertension Date: 2014-11-10 Impact factor: 10.190
Authors: T Scott Bowen; Norman Mangner; Sarah Werner; Stefanie Glaser; Yvonne Kullnick; Andrea Schrepper; Torsten Doenst; Andreas Oberbach; Axel Linke; Leif Steil; Gerhard Schuler; Volker Adams Journal: J Appl Physiol (1985) Date: 2014-10-30
Authors: Diewertje I Bink; Katja Ritz; Eleonora Aronica; Louise van der Weerd; Mat J A P Daemen Journal: J Cereb Blood Flow Metab Date: 2013-08-21 Impact factor: 6.200
Authors: Paulo W Pires; Saavia S Girgla; Guillermo Moreno; Jonathon L McClain; Anne M Dorrance Journal: Am J Physiol Heart Circ Physiol Date: 2014-07-11 Impact factor: 4.733
Authors: Gilles Kauffenstein; Sophie Tamareille; Fabrice Prunier; Charlotte Roy; Audrey Ayer; Bertrand Toutain; Marie Billaud; Brant E Isakson; Linda Grimaud; Laurent Loufrani; Pascal Rousseau; Pierre Abraham; Vincent Procaccio; Hannah Monyer; Cor de Wit; Jean-Marie Boeynaems; Bernard Robaye; Brenda R Kwak; Daniel Henrion Journal: Arterioscler Thromb Vasc Biol Date: 2016-06-02 Impact factor: 8.311
Authors: Francesc Jiménez-Altayó; Julia Marzi; María Galan; Ana Paula Dantas; Marisa Ortega; Santiago Rojas; Gustavo Egea; Katja Schenke-Layland; Elena Jiménez-Xarrié; Anna M Planas Journal: J Cereb Blood Flow Metab Date: 2021-09-02 Impact factor: 6.960